Nektar Therapeutics (0UNL.L)
USD 1.01
(-1.02%)
USD 1.01
(-1.02%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 53.47 Million USD | -24.06% |
| 2022 | 70.42 Million USD | -8.56% |
| 2021 | 77.01 Million USD | -42.29% |
| 2020 | 133.43 Million USD | 43.11% |
| 2019 | 93.24 Million USD | -92.02% |
| 2018 | 1.16 Billion USD | 321.74% |
| 2017 | 277.16 Million USD | 104.97% |
| 2016 | 135.22 Million USD | -31.25% |
| 2015 | 196.68 Million USD | 14.23% |
| 2014 | 172.17 Million USD | 55.94% |
| 2013 | 110.41 Million USD | 117.5% |
| 2012 | 50.76 Million USD | 2.37% |
| 2011 | 49.58 Million USD | -62.82% |
| 2010 | 133.37 Million USD | 225.43% |
| 2009 | 40.98 Million USD | -25.69% |
| 2008 | 55.14 Million USD | -56.06% |
| 2007 | 125.51 Million USD | 25.98% |
| 2006 | 99.62 Million USD | 10.35% |
| 2005 | 90.28 Million USD | -4.43% |
| 2004 | 94.47 Million USD | 3.16% |
| 2003 | 91.57 Million USD | 4.27% |
| 2002 | 87.82 Million USD | 19.82% |
| 2001 | 73.29 Million USD | 41.97% |
| 2000 | 51.62 Million USD | 24.83% |
| 1999 | 41.35 Million USD | 89.76% |
| 1998 | 21.79 Million USD | 34.13% |
| 1997 | 16.24 Million USD | 100.6% |
| 1996 | 8.1 Million USD | 80.0% |
| 1995 | 4.5 Million USD | 104.55% |
| 1994 | 2.2 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 13.74 Million USD | 4.91% |
| 2024 Q1 | 13.1 Million USD | -21.06% |
| 2023 FY | 53.47 Million USD | -24.06% |
| 2023 Q1 | 14.53 Million USD | -7.95% |
| 2023 Q2 | 13.5 Million USD | -7.08% |
| 2023 Q3 | 11.71 Million USD | -13.27% |
| 2023 Q4 | 16.6 Million USD | 41.74% |
| 2022 Q2 | 16.47 Million USD | -15.57% |
| 2022 Q1 | 19.5 Million USD | 3.51% |
| 2022 FY | 70.42 Million USD | -8.56% |
| 2022 Q4 | 15.79 Million USD | -15.35% |
| 2022 Q3 | 18.65 Million USD | 13.25% |
| 2021 Q1 | 17.89 Million USD | -6.52% |
| 2021 Q2 | 20.66 Million USD | 15.49% |
| 2021 FY | 77.01 Million USD | -42.29% |
| 2021 Q3 | 19.61 Million USD | -5.1% |
| 2021 Q4 | 18.84 Million USD | -3.9% |
| 2020 Q3 | 24.46 Million USD | -43.21% |
| 2020 Q2 | 43.07 Million USD | -7.89% |
| 2020 FY | 133.43 Million USD | 43.11% |
| 2020 Q4 | 19.13 Million USD | -21.76% |
| 2020 Q1 | 46.76 Million USD | 67.77% |
| 2019 Q3 | 24.29 Million USD | 32.76% |
| 2019 Q1 | 22.78 Million USD | -29.61% |
| 2019 FY | 93.24 Million USD | -92.02% |
| 2019 Q4 | 27.87 Million USD | 14.75% |
| 2019 Q2 | 18.29 Million USD | -19.69% |
| 2018 Q4 | 32.36 Million USD | 40.85% |
| 2018 Q3 | 22.97 Million USD | -97.88% |
| 2018 FY | 1.16 Billion USD | 321.74% |
| 2018 Q2 | 1.08 Billion USD | 3349.56% |
| 2018 Q1 | 31.37 Million USD | -63.4% |
| 2017 Q3 | 147.25 Million USD | 475.21% |
| 2017 Q1 | 18.59 Million USD | -39.71% |
| 2017 Q2 | 25.6 Million USD | 37.66% |
| 2017 Q4 | 85.71 Million USD | -41.79% |
| 2017 FY | 277.16 Million USD | 104.97% |
| 2016 Q4 | 30.84 Million USD | 5.27% |
| 2016 FY | 135.22 Million USD | -31.25% |
| 2016 Q2 | 25.06 Million USD | -49.89% |
| 2016 Q1 | 50.01 Million USD | 61.3% |
| 2016 Q3 | 29.3 Million USD | 16.93% |
| 2015 Q3 | 53.19 Million USD | 338.62% |
| 2015 FY | 196.68 Million USD | 14.23% |
| 2015 Q2 | 12.12 Million USD | -87.92% |
| 2015 Q1 | 100.35 Million USD | 657.24% |
| 2015 Q4 | 31 Million USD | -41.71% |
| 2014 Q1 | 11.86 Million USD | -46.52% |
| 2014 Q2 | 23.4 Million USD | 97.28% |
| 2014 Q3 | 123.65 Million USD | 428.31% |
| 2014 Q4 | 13.25 Million USD | -89.28% |
| 2014 FY | 172.17 Million USD | 55.94% |
| 2013 Q1 | 11.34 Million USD | -18.14% |
| 2013 FY | 110.41 Million USD | 117.5% |
| 2013 Q4 | 22.18 Million USD | -53.81% |
| 2013 Q3 | 48.03 Million USD | 66.48% |
| 2013 Q2 | 28.85 Million USD | 154.35% |
| 2012 Q3 | 11.18 Million USD | -32.14% |
| 2012 Q4 | 13.85 Million USD | 23.89% |
| 2012 Q1 | 9.24 Million USD | -10.55% |
| 2012 Q2 | 16.48 Million USD | 78.33% |
| 2012 FY | 50.76 Million USD | 2.37% |
| 2011 Q2 | 9.19 Million USD | 14.37% |
| 2011 FY | 49.58 Million USD | -62.82% |
| 2011 Q4 | 10.33 Million USD | -53.1% |
| 2011 Q3 | 22.03 Million USD | 139.69% |
| 2011 Q1 | 8.03 Million USD | -77.09% |
| 2010 Q4 | 35.07 Million USD | 10.72% |
| 2010 Q1 | 28.94 Million USD | -0.48% |
| 2010 FY | 133.37 Million USD | 225.43% |
| 2010 Q2 | 37.67 Million USD | 30.18% |
| 2010 Q3 | 31.68 Million USD | -15.91% |
| 2009 Q1 | 4.61 Million USD | -74.6% |
| 2009 Q4 | 29.08 Million USD | 541.7% |
| 2009 Q3 | 4.53 Million USD | 64.38% |
| 2009 FY | 40.98 Million USD | -25.69% |
| 2009 Q2 | 2.75 Million USD | -40.22% |
| 2008 Q1 | 7.43 Million USD | -82.19% |
| 2008 FY | 55.14 Million USD | -56.06% |
| 2008 Q4 | 18.15 Million USD | 12.85% |
| 2008 Q3 | 16.09 Million USD | 19.45% |
| 2008 Q2 | 13.47 Million USD | 81.29% |
| 2007 Q1 | 28.49 Million USD | -0.93% |
| 2007 FY | 125.51 Million USD | 25.98% |
| 2007 Q4 | 41.72 Million USD | 44.56% |
| 2007 Q3 | 28.86 Million USD | 9.22% |
| 2007 Q2 | 26.42 Million USD | -7.25% |
| 2006 FY | 99.62 Million USD | 10.35% |
| 2006 Q1 | 19.96 Million USD | -8.14% |
| 2006 Q2 | 23.45 Million USD | 17.46% |
| 2006 Q4 | 28.76 Million USD | 4.77% |
| 2006 Q3 | 27.45 Million USD | 17.07% |
| 2005 FY | 90.28 Million USD | -4.43% |
| 2005 Q4 | 21.73 Million USD | -19.96% |
| 2005 Q2 | 20.45 Million USD | -12.0% |
| 2005 Q1 | 23.23 Million USD | -8.2% |
| 2005 Q3 | 27.15 Million USD | 32.78% |
| 2004 Q2 | 21.79 Million USD | -6.44% |
| 2004 Q3 | 24.06 Million USD | 10.44% |
| 2004 FY | 94.47 Million USD | 3.16% |
| 2004 Q4 | 25.31 Million USD | 5.17% |
| 2004 Q1 | 23.29 Million USD | 2.09% |
| 2003 Q3 | 23.81 Million USD | -0.93% |
| 2003 Q2 | 24.04 Million USD | 14.99% |
| 2003 FY | 91.57 Million USD | 4.27% |
| 2003 Q4 | 22.81 Million USD | -4.19% |
| 2003 Q1 | 20.9 Million USD | -0.98% |
| 2002 FY | 87.82 Million USD | 19.82% |
| 2002 Q4 | 21.11 Million USD | -0.78% |
| 2002 Q3 | 21.27 Million USD | 3.4% |
| 2002 Q2 | 20.57 Million USD | -17.21% |
| 2002 Q1 | 24.85 Million USD | 13.1% |
| 2001 Q3 | 20.42 Million USD | 21.59% |
| 2001 Q1 | 14.09 Million USD | 7.23% |
| 2001 FY | 73.29 Million USD | 41.97% |
| 2001 Q2 | 16.79 Million USD | 19.17% |
| 2001 Q4 | 21.97 Million USD | 7.59% |
| 2000 Q1 | 10.63 Million USD | -18.66% |
| 2000 FY | 51.62 Million USD | 24.83% |
| 2000 Q3 | 14.06 Million USD | 1.97% |
| 2000 Q4 | 13.14 Million USD | -6.51% |
| 2000 Q2 | 13.78 Million USD | 29.68% |
| 1999 Q4 | 13.07 Million USD | 23.01% |
| 1999 Q3 | 10.62 Million USD | 7.6% |
| 1999 FY | 41.35 Million USD | 89.76% |
| 1999 Q2 | 9.87 Million USD | 26.95% |
| 1999 Q1 | 7.78 Million USD | 22.17% |
| 1998 Q4 | 6.36 Million USD | 30.41% |
| 1998 Q3 | 4.88 Million USD | -26.89% |
| 1998 Q2 | 6.67 Million USD | 72.81% |
| 1998 FY | 21.79 Million USD | 34.13% |
| 1998 Q1 | 3.86 Million USD | -19.31% |
| 1997 Q1 | 3.17 Million USD | 44.41% |
| 1997 Q3 | 4.3 Million USD | 8.46% |
| 1997 Q4 | 4.79 Million USD | 11.16% |
| 1997 FY | 16.24 Million USD | 100.6% |
| 1997 Q2 | 3.97 Million USD | 25.06% |
| 1996 Q3 | 1.8 Million USD | 28.57% |
| 1996 Q4 | 2.2 Million USD | 22.22% |
| 1996 Q1 | 1.5 Million USD | 87.5% |
| 1996 FY | 8.1 Million USD | 80.0% |
| 1996 Q2 | 1.4 Million USD | -6.67% |
| 1995 Q1 | 600 Thousand USD | -85.37% |
| 1995 Q2 | 1 Million USD | 66.67% |
| 1995 Q4 | 800 Thousand USD | -20.0% |
| 1995 Q3 | 1 Million USD | 0.0% |
| 1995 FY | 4.5 Million USD | 104.55% |
| 1994 Q1 | -600 Thousand USD | 0.0% |
| 1994 FY | 2.2 Million USD | 0.0% |
| 1994 Q4 | 4.1 Million USD | 920.0% |
| 1994 Q2 | -700 Thousand USD | -16.67% |
| 1994 Q3 | -500 Thousand USD | 28.57% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 153.732% |
| Dynavax Technologies Corporation | 182.11 Million USD | 70.635% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 89.789% |
| Perrigo Company plc | 1.68 Billion USD | 96.818% |
| Illumina, Inc. | 2.74 Billion USD | 98.051% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 99.649% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 659.042% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 99.798% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 98.979% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -432.543% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 99.527% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 371.476% |
| Waters Corporation | 1.76 Billion USD | 96.964% |
| Biogen Inc. | 7.3 Billion USD | 99.268% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 217.988% |
| Evolus, Inc. | 140.52 Million USD | 61.944% |
| Adicet Bio, Inc. | -6.09 Million USD | 976.976% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -261.484% |
| bluebird bio, Inc. | -4.03 Million USD | 1426.998% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 26.81% |
| FibroGen, Inc. | 128.9 Million USD | 58.513% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 98.457% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 271.582% |
| Homology Medicines, Inc. | -7.22 Million USD | 839.77% |
| Geron Corporation | -123.5 Million USD | 143.301% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 96.477% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 85.228% |
| Myriad Genetics, Inc. | 476.4 Million USD | 88.775% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 18414.384% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 113.41% |
| Zoetis Inc. | 5.83 Billion USD | 99.083% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -17607.947% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 97.535% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 97.192% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 99.379% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 17749.505% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 93.131% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 17185.623% |
| Verastem, Inc. | -62 Thousand USD | 86354.839% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 78.131% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 162.756% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 95.107% |
| OPKO Health, Inc. | 318.12 Million USD | 83.19% |
| Exelixis, Inc. | 1.75 Billion USD | 96.957% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 97.105% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 88.763% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 2.21 Million USD | -2314.357% |
| Imunon, Inc. | -720 Thousand USD | 7527.448% |
| Blueprint Medicines Corporation | 236.58 Million USD | 77.396% |
| Insmed Incorporated | 239.63 Million USD | 77.684% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 91.603% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -208.782% |
| TG Therapeutics, Inc. | 219.1 Million USD | 75.593% |
| Incyte Corporation | 3.44 Billion USD | 98.446% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 84.45% |